Skip to main content
TeamingIndex
Unclaimed profileSeeded from SAM.gov and USAspending public records
Claim this profileCapability statement (.md)

INTEGRAL MOLECULAR INC

UEIDY9KSWE8EJB8CAGE3PJG4NAICS541714
  • SAM active
  • No verified credentials yet
  • CMMCNot on file
  • SPRSNone
  • FCLVisible to paid members
  • Small Business

Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works

36-mo obligations
$7.1M
Awards on record
7
Contract vehicles
0
Verified credentials
0

Compliance posture: unverified (SAM.gov baseline only)

INTEGRAL MOLECULAR INC has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0

Claim this profile

About INTEGRAL MOLECULAR INC

INTEGRAL MOLECULAR INC is a SAM.gov-registered entity based in PHILADELPHIA, PA 19104-5640. UEI DY9KSWE8EJB8; CAGE 3PJG4; primary NAICS 541714. Compliance posture not provided. Active SAM registration.
Headquarters
PHILADELPHIA, PA 19104-5640

Identifiers

UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.

  • UEIDY9KSWE8EJB8
  • CAGE3PJG4

Capabilities & differentiators

No capability narrative yet

The company has not published a capability narrative. Its SAM.gov registration, NAICS codes and award history are below.
Is this your company? Claim it

Compliance posture

Every credential shows who vouches for it: verified by TeamingIndex, or self-attested by the contractor.

No compliance posture published yet

Compliance facts appear once the company claims this profile and publishes them.
Is this your company? Claim it

Facility clearance

Facility clearance: visible to paid members

Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans

Past performance

Recompete RadarLearn more about past performance
Prime awards from USAspending.gov (FPDS), synced nightly. Recompete windows use the potential end date (base plus all options).
36-month obligations
$7.1M
Awards on record
7
Top funding agencies
National Institutes of Health · Department of State

Awards

  • 75N93025C00019

    Recompete 18+ mo: Potential end May 31, 2028 (18 months away)

    ANTIBODY REAGENTS FOR IMMUNOLOGIC ANALYSIS OF UNDER-REPRESENTED MAMMALIAN MODELS

    Department of Health and Human Services · National Institutes of Health

    Obligated
    $1.5M
    Period of performance
    Jun 1, 2025 – May 31, 2028

  • 75N93024C00071

    Recompete 6–12 mo: Potential end Sep 15, 2027 (10 months away)

    TO DISCOVER AND CHARACTERIZE B CELL EPITOPES AGAINST THE VIRAL PATHOGENS RVFV, CCHFV, AND EV-D68.

    Department of Health and Human Services · National Institutes of Health

    Obligated
    $4.9M
    Period of performance
    Sep 16, 2024 – Sep 15, 2027
    AI brief for award 75N93024C00071Bid team for the recompete of award 75N93024C00071

  • 19GE5026P0122

    Recompete < 6 mo: Potential end Jan 20, 2027 (2 months away)

    ACQUISITION OF LABORATORY SUPPLIES ON BEHALF OF AFRIMS, BANGKOK, THAILAND

    Department of State

    Obligated
    $30.3K
    Period of performance
    Sep 22, 2026 – Jan 20, 2027
    AI brief for award 19GE5026P0122Bid team for the recompete of award 19GE5026P0122

  • 75N94025P00526

    Completed: Period of performance ended Nov 21, 2025

    NICHD: SERVICE: MEMBRANE PROTEOME ARRAY SCREENING SERVICE FOR NOVEL MONOCLONAL ANTIBODY TARGET IDENTIFICATION

    Department of Health and Human Services · National Institutes of Health

    Obligated
    $66.9K
    Period of performance
    Aug 27, 2025 – Nov 21, 2025

  • 75N93023C00036

    Completed: Period of performance ended Aug 31, 2025

    SBIR TOPIC 118: REAGENTS FOR IMMUNOLOGIC ANALYSIS OF NON-MAMMALIAN AND UNDERREPRESENTED MAMMALIAN MODELS.

    Department of Health and Human Services · National Institutes of Health

    Obligated
    $600K
    Period of performance
    Sep 1, 2023 – Aug 31, 2025

  • 19GE5024P0045

    Completed: Period of performance ended Nov 12, 2024

    U.S. EMBASSY BANGKOK, THAILAND. LABORATORY SUPPLIES.

    Department of State

    Obligated
    $61.2K
    Period of performance
    Jul 23, 2024 – Nov 12, 2024

  • 75N93024P00100

    Completed: Period of performance ended Jan 31, 2024

    MEMBRANE PROTEOME ARRAY SERVICE (AMBIS #2194825)

    Department of Health and Human Services · National Institutes of Health

    Obligated
    $16.2K
    Period of performance
    Nov 21, 2023 – Jan 31, 2024

Contract vehicles

Learn more about GWACs, IDIQs and contract vehicles

No contract vehicles on file

This company has not listed GWAC, IDIQ, GSA Schedule or OTA consortium holdings.
Browse vehicle holders

Proven teaming graph

Learn more about sub-award reporting (FSRS)
Who INTEGRAL MOLECULAR INC has actually worked with, from sub-awards that prime contractors report to the government. Use it to see which primes already trust this company.

Primes it has worked under

  • BATTELLE MEMORIAL INSTITUTE

    UEI F125YU6SWK59

    $147.8K

    Subcontractor to this prime · 1 sub-award · latest Dec 23, 2025

    • Office of Assistant Secretary for Preparedness and Response
    • “THREE LOTS OF RVPS WITH RENILLA LUCIFERASE”

Subcontractors it has used

No reported sub-awards as a prime contractor.

Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · as of Nov 9, 2026 · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.

SBIR/STTR portfolio

Learn more about SBIR/STTR Phase IIIAbout SBIR/STTR (opens in a new tab)
Small Business Innovation Research and Technology Transfer awards: early-stage federal R&D money this company has won.

SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects

Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.

Awards on record
50 awards
Total awarded
$34,006,611
By phase
  • SBIR Phase I: 30
  • SBIR Phase II: 15
  • STTR Phase I: 3
  • STTR Phase II: 2
By agency
  • Department of Health and Human Services: 50
Active projects
2 projects
Projects whose contract end date is today or later.
Phase II ending within 12 months
1 project
Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
By year
  • 2025: 2
  • 2024: 2
  • 2023: 2
  • 2022: 3
  • 2021: 1
  • 2020: 2
  • 2018: 3
  • 2017: 1
  • 2015: 1
  • 2014: 3
  • 2012: 2
  • 2011: 2
  • 2009: 2
  • 2008: 2
  • 2007: 2
  • 2006: 3
  • 2005: 5
  • 2004: 4
  • 2003: 4
  • 2002: 4

Awards (most recent first)

  • High-throughput Discovery of Antibodies against Understudied Membrane Proteins using mRNA

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2025 · $923,143

    Aug 15, 2025 – Jan 31, 2028

    • Active

    Solicitation PA24-245 (2024) · Topic 300

  • ANTIBODY REAGENTS FOR IMMUNOLOGIC ANALYSIS OF UNDER-REPRESENTED MAMMALIAN MODELS

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2025 · $1,500,000

    • Direct to Phase II

    Solicitation PHS 2025-1 (2025) · Topic 141

  • Specificity Screening Drug Development Tool for Biotherapeutic Safety

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2024 · $1,846,470

    Sep 8, 2024 – Aug 31, 2027

    • Active
    • Ends Aug 2027

    Solicitation PAR23-219 (2023) · Topic 400

  • Development of Safe and Rapid Reporter Viruses for Studying Pathogenic and Pandemic Viruses

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2024 · $577,030

    Jul 1, 2024 – Jun 30, 2026

    Solicitation PA23-230 (2023) · Topic NIAID

  • High-throughput Discovery of Antibodies against Understudied Membrane Proteins

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2023 · $295,924

    May 1, 2023 – Apr 30, 2024

    Solicitation PA22-176 (2022) · Topic 300

  • Reagents for Immunologic Analysis of Under-represented Mammalian Models

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2023 · $600,000

    Solicitation PHS-2023-1 (2023) · Topic 118

  • Identifying Regulators of Cellular Aging that can Prevent Alzheimer's Disease

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2022 · $447,566

    Jun 1, 2022 – Nov 30, 2023

    Solicitation PAS19-316 (2019) · Topic R

  • Development of Claudin MAbs for Treating Solid Tumors

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2022 · $1,703,866

    Jun 1, 2022 – Nov 30, 2024

    Solicitation PA21-259 (2021) · Topic NCI

  • ADJUVANT TARGET DISCOVERY FOR VACCINES AND FOR AUTOIMMUNE AND ALLERGIC DISEASES.

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2022 · $600,000

    Solicitation PHS-2022-1 (2021) · Topic 104

  • Development of Nav1.7 Monoclonal Antibodies for Treating Pain

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2021 · $474,833

    Sep 20, 2021 – Aug 31, 2023

    Solicitation NS20-011 (2020) · Topic NINDS

  • Next Generation Specificity Screening for Biotherapeutics using an Extracellular Proteome Array

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2020 · $1,640,679

    Jul 1, 2020 – Dec 31, 2022

    Solicitation PA19-272 (2019) · Topic 400

  • Development of Kv1.3 Monoclonal Antibodies Targeting TEM Cells for Treating Autoimmune Disorders

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2020 · $1,809,645

    Apr 1, 2020 – Sep 30, 2022

    Solicitation PA18-574 (2018) · Topic 400

  • Development of CB1 Monoclonal Antibodies for Treating NASH

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2018 · $1,475,011

    Sep 7, 2018 – May 31, 2021

    Solicitation PA17-130 (2017) · Topic 300

  • Identifying New Immunomodulatory Targets for Alzheimers and Other Neurodegenerative Diseases

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $414,721

    Sep 1, 2018 – May 31, 2020

    Solicitation PAS17-064 (2017) · Topic NIA

  • Identifying Agonist MAbs against GPCRs

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $355,360

    Aug 8, 2018 – Jul 31, 2020

    Solicitation PA17-302 (2017) · Topic 300

  • High-throughput Identification of Membrane Protein MAbs

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2017 · $1,573,082

    Jan 10, 2017 – Sep 30, 2019

    Solicitation PA15-269 (2015) · Topic 400

  • High-throughput Identification of Membrane Protein MAbs

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2015 · $224,752

    Feb 1, 2015 – Jun 30, 2016

    Solicitation PA14-071 (2015) · Topic 400

  • Development of P2X3 Ion Channel MAbs for the Treatment of Pain

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2014 · $1,428,459

    Sep 15, 2014 – Feb 28, 2018

    Solicitation PA11-335 (2011) · Topic 100

  • Development of High-expressing Ion Channels for Research and Therapeutic Applicat

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2014 · $471,745

    Sep 5, 2014 – May 31, 2016

    Solicitation PA11-335 (2015) · Topic 300

  • Engineering of membrane protein chemosensors for therapeutic research

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2014 · $1,213,215

    Dec 1, 2013 – May 31, 2018

    Solicitation PA11-134 (2011) · Topic NIDCD

  • Engineering Stable, Soluble, and Trimeric HIV gp140 by Paired Cys Scanning

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2012 · $546,301

    Solicitation PA10-123 (2012) · Topic NIAID · Research partner: Stub

  • Phage Display Isolation of Antibodies against Antigenically Conserved Membrane Pr

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2012 · $214,214

    Solicitation PA11-096 (2012) · Topic NIGMS · Research partner: Stub

  • High-throughput Epitope Mapping of Anti-Viral Antibodies

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2011 · $242,376

    Solicitation PA10-050 (2011) · Topic NIAID · Research partner: Stub

  • Isolation of Monoclonal Antibodies against Membrane Proteins

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2011 · $660,813

    Solicitation PA08-114 (2011) · Topic NIGMS · Research partner: Stub

  • Development of taste receptor ligands using structure-activity studies

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2009 · $696,243

    Solicitation PHS2009-2 (2009)

Showing the 25 most recent of 50 awards.

Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026

FedRAMP offerings

Learn more about the FedRAMP Marketplace
Cloud services this company lists on the FedRAMP Marketplace, the government's record of cloud authorizations.

No FedRAMP Marketplace listing

No FedRAMP Marketplace listing is linked to this company. Cloud providers appear here automatically once FedRAMP lists their offering.
Find FedRAMP-authorized companies

Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded

Exclusions & screening

Exclusions about SAM.gov exclusionsScreening list about the Consolidated Screening List
Checks a prime runs before teaming: SAM.gov exclusions (debarment and suspension) and the government's Consolidated Screening List for export and sanctions lists.

SAM.gov exclusions

Not yet checked against SAM.gov exclusions.

Search exclusions on SAM.gov (opens in a new tab)

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.

Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded

Consolidated Screening List

No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).

The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.

Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026

GSA CALC+ rate benchmark

Learn more about GSA CALC+ labor rates
Hourly ceiling rates this company was awarded on GSA contracts, compared with the market for similar labor categories. Ceiling rates are the most an agency can be charged, not prices paid.

No GSA CALC+ rates on record

Companies with a GSA Multiple Award Schedule contract appear here after CALC+ publishes their awarded labor rates.
See GSA MAS holders

Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded

NAICS, PSC & socio-economic status

Learn more about NAICS size standards
Industry codes and small-business programs reported in SAM.gov.

NAICS codes

  • 541714Research and Development in Biotechnology (except Nanobiotechnology)PrimarySmall business under this code’s size standard

SAM.gov reports this entity as small under 1 of 1 NAICS code. Size is determined per code (SBA size standards).

Socio-economic status

Learn more about small business set-asides

Product & service codes (PSC)

No PSC codes reported.

Teaming preferences

Learn more about teaming agreements and joint ventures

This company has not published teaming preferences.

SAM.gov teaming eligibility: Eligible to be proposed as a team member: active SAM.gov registration and no exclusion.

Business development contact

No BD contact published

Contact details appear once the company claims this profile.
Is this your company? Claim it

Corporate hierarchy

Affiliation & size about affiliation and size
Immediate parent and highest-level owner as reported in SAM.gov.

No parent entity reported in SAM.gov.

SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.

Data sources & provenance

Who stands behind each fact on this page, and how to correct it.

  • SAM.gov

    Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.

  • USAspending.gov

    Prime award history and obligations (FPDS), synced nightly.

  • The contractor

    Nothing yet: this profile has not been claimed by the company.

  • TeamingIndex verification

    Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.

Corrections

Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)

Machine-readable: capability.md schema.org JSON-LD embedded in this page.

Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.

Teaming

Ready to team with INTEGRAL MOLECULAR INC?

Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.

Claim this profileCapability statement (.md)